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ASSESSING THE MAJOR DRIVERS FOR THE INCREASED
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OBJECTIVES: This burden of illness study was conducted to assess the 12-month
resource utilization and health care costs, along with the major drivers of those costs,
associated with an incident diagnosis of prostate cancer (PC). METHODS: An analysis
of incident PC patients identiﬁ ed using a claims database, was performed, for 2005, 
2006, and 2007. PC patients and the age and gender matched comparator group (1:4)
for each year, were required to have continuous enrollment in a plan and no prostate 
cancer diagnoses during the 18 months prior to the ﬁ rst diagnosis of prostate cancer
in the year. The PC and comparison groups were each described in terms of their 
health care service use and health care costs, which were compared, using nonpara-
metric Wilcoxon rank-sum tests, with mean values reported here for 2007. RESULTS:
There were 21,520 men diagnosed with PC in 2007, in this database, and we selected 
86,080 controls. The mean health care cost for the men diagnosed with PC was
$19,979 vs. $7,105 for controls; p  0.001. The primary drivers for this nearly triple 
cost difference between the two groups were: hospitalizations ($6,292 vs. $2,375;
p  0.001); radiology tests ($3,014 vs. $348; p  0.001); prescription drugs ($2,293 
vs. $1,439; p  0.001); and laboratory tests ($880 vs. $203; p  0.001). Resource
utilization over the 12-month period showed that the men with PC, when compared
to the control group, had a signiﬁ cantly greater (p  0.001) mean number of hospi-
talizations (0.4 vs. 0.2; p  0.001); radiology tests (10 vs. 2; p  0.001); prescription
drugs (22 vs. 16; p  0.001); and laboratory tests (18 vs. 8; p  0.001). CONCLU-
SIONS: The signiﬁ cantly higher 12-month resource utilization and health care costs
noted in men diagnosed with PC, compared to age and gender matched controls, are 
primarily driven by an increased need for hospitalizations, radiology tests, prescription 
drugs, and laboratory tests.
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OBJECTIVES: To characterize health care resource use and costs in US women with 
incident metastatic breast cancer receiving chemotherapy as their principal treatment
modality. METHODS: Using a retrospective cohort design and a large private health 
insurance claims database (2000–2005), we identiﬁ ed all women initiating chemo-
therapy for incident metastatic breast cancer with no evidence of concomitant or 
subsequent receipt of hormonal therapy or trastuzumab. Health care resource use
(inpatient, outpatient, medications) and costs were tallied on a cumulative basis from 
date of chemotherapy initiation (ie, index date) to date of disenrollment from the 
health plan (in most instances, presumably due to death) or the end of the study period,
whichever occurred ﬁ rst. Study measures were summarized using Kaplan-Meier 
Sample Average (KMSA) method; 95% CIs were generated using nonparametric
bootstrapping. Reimbursed amounts were used as a proxy for costs. RESULTS: The
study population consisted of 820 women; mean (SD) age was 58.4 (12.0) years. Over 
a mean follow-up of 692 days (range: 3 to 2,182), study subjects averaged 1.1 hospital 
admissions, 6.8 inpatient days, and 62.4 physician ofﬁ ce and hospital outpatient visits. 
Mean (95% CI) cumulative total health care costs were $91,400 ($83,804, $99,050)
per patient over this period. Outpatient chemotherapy constituted 24% of total health 
care costs; comparable percentages for inpatient care, outpatient services, and all other 
outpatient pharmacotherapy were 19%, 32%, and 24%, respectively. CONCLU-
SIONS: Health care costs are high in US women with incident metastatic breast cancer 
receiving chemotherapy as their principal treatment modality. This study provides 
important additional information on the cost of treatment of this disease.
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OBJECTIVES: To review the incidence rate, mortality and burden of illness in cervical 
cancer in the United States (US). METHODS: The information was retrieved from the
WHO, World Bank, US National Cancer Institute, American Cancer Society, clinical-
trials.gov, Medline and relevant grey literature from 1990 to 2008. We summarized
epidemiological information such as numbers of diagnosed cases and deaths, and
associated burden of illness was the outcome of interest. RESULTS: Cervical cancer
is the second most frequent cancer in women worldwide and the leading cause of 
cancer deaths in the developing world, leading to up to 240,000 deaths per year
(WHO, 2006). There were 11,070 new cases and 3870 estimated deaths in 2008 in
the United States according to SEER data compared to 265,884 cases and 204,406 
deaths in Asia and Africa in 2007 (WHO). The annual economic burden of cervical 
cancer in the US has been estimated in 2004 as US$1.7 bn (National Cancer Institute) 
with direct medical costs estimated as $300–400 m (Insinga et al 2005). The cost of 
treating a single case of localized (early-stage) cervical cancer was estimated in 2000
as US$20,255, while the cost of treating a single case of distant (late-stage) disease 
averaged $36,912 (Chesson et al 2004). Overall annual cervical cancer prevention and 
treatment costs were $26,415 per 1,000 females, with routine cervical cancer screening 
costs were $16,746 per 1,000 females (Insinga et al 2004). The total productivity loss 
in year 2000 due to cervical cancer mortality was estimated at US$1.3 billion (Insinga
2006). The average number of years of life lost per woman who died of cervical cancer 
in the United States was 26.3 years (SEER 2005). CONCLUSIONS: The incidence of 
cervical cancer has decreased in the US in recent years but it still poses a major chal-
lenge to the US and developing countries.
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OBJECTIVES: Costs of all-stage prostate cancer management over time have been
previously examined and are described as U-shaped. There is less information speciﬁ -
cally with regard to late-stage prostate cancer (PC), where patterns of care may differ.
The objective of this study is to examine costs of management of regionally metasta-
sized (i.e. M1) PC patterns. METHODS: SEER-Medicare patients (pts) aged 65 and 
diagnosed with M1 PC between 1994–2002 were selected. The sample was reﬁ ned to 
pts surviving 18 to 36 months post-diagnosis. Mean monthly service (physician, out-
patient facility, hospital, DME, hospice, home health care, and skilled nursing facility
(SNF))-speciﬁ c costs were calculated using Medicare payments to providers. Cost 
patterns at 6 months pre-diagnosis, 6-months post-diagnosis, and 12 months before 
death were plotted. Graphs were stratiﬁ ed by whether or not patients received treat-
ment for PC (radiation, surgery, drug therapy). RESULTS: A total of 1678 pts were 
available for the analysis based on the inclusion criteria. Approximately 88% received 
treatment. A U-shaped cost accrual pattern was observed for treated patients and
patients managed by watchful waiting (WW). A peak in costs was observed at month
of diagnosis, and a higher peak at time of death. The magnitude of costs was higher
among treated patients, with mean costs reaching approximately $7500 at death 
(versus $4000 among patients under WW). Among cost components, hospital services 
contributed the most to cost accrual, more so in untreated patients. Treated patients
cost more than untreated patients with regards to physician services, while untreated 
patients appeared to incur SNF costs more consistently across the observation period. 
CONCLUSIONS: In late-stage prostate cancer, costs of care assume a U-shape, with
the highest costs being incurred at diagnosis and at the end of life. Patterns and com-
ponents of care differed somewhat between treated and untreated patients while hos-
pital services consistently accounted for the most spending.
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OBJECTIVES: Metastatic breast cancer (MBC) is incurable, but survival and quality
of life may be prolonged for years with available therapies; however, costs associated
with MBC and its treatment are not fully deﬁ ned. We conducted this research to
compile and synthesize the published research concerning the health economics of 
MBC. METHODS: We systematically reviewed MEDLINE-indexed, English-
language literature, using keyword searches to identify articles published in the 5 years
before October 2008. We excluded articles related to supportive therapy, early dis
ease, diagnosis, non-economic issues, regions outside North America, Europe or Aus-
tralia, or economic methods. Additional articles were added from searches of non-
MEDLINE-indexed sources such as organization and government websites. RESULTS:
Of 43 articles identiﬁ ed from MEDLINE, 19 were included; an additional 13 articles
and abstracts were added from non-MEDLINE-indexed sources, for a total of 32 arti-
cles and abstracts. No comprehensive study was found which included estimates of the 
total MBC economic burden across all treatment options. Most (7 of 10) analyses of 
the per-patient direct MBC costs originate from the US. The only published national
MBC costs were derived from UK data. Thirteen economic models have been published
showing that numerous treatments are cost-effective, yet generally provide only small 
improvements in survival. Nine published economic models evaluate hormonal thera-
pies; 7 compare letrozole and tamoxifen and generally show letrozole to be cost-
effective. In health technology assessments, trastuzumab, capecitabine, and gemcitabine 
have been judged cost-effective, with inconsistent results for vinorelbine. CONCLU-
SIONS: There is no known recent publication concerning the overall economic burden 
of MBC. However, many publications assess the costs and cost-effectiveness of avail-
able treatments. Models show that some of these treatments, most notably letrozole,
are cost-effective. More MBC economic evaluations should be published to better 
inform the use of new treatment modalities in a variety of health care settings.
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OBJECTIVES: Head and neck cancer (HNC) is the sixth most common neoplasm in 
the U.S.; approximately $3.2 billion are spent annually for treatment. The projected 
